Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZREFQ)

• Drug Name: Eslicarbazepine Drug Info
• Synonyms: Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix

Indication

Disease Entry	ICD 11	Status	REF
Seizure disorder	8A6Z	Approved	[1]

• Therapeutic Class: Neurology Agents
• Cross-matching ID:
  PubChem CID: 9881504
  CAS Number: CAS 104746-04-5
  TTD Drug ID: DMZREFQ
  INTEDE Drug ID: DR0624

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[5]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[6]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[7]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[8]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[9]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[10]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[11]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[12]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[13]
Butacaine	DM584TM	Pain	MG30-MG3Z	Approved	[14]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[15]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[16]
Lacosamide	DMVM6QR	Convulsion	8A68.Z	Approved	[3]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[17]
Tolperisone	DMA2GHJ	Muscle spasm	MB47.3	Approved	[18]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[19]
Oxcarbazepine	DM5PU6O	Epilepsy	8A60-8A68	Approved	[20]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[21]
QX-314	DMAV2FM	Pain	MG30-MG3Z	Terminated	[22]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Voltage-gated sodium channel (Nav)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lacosamide	DMVM6QR	Convulsion	8A68.Z	Approved	[3]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[3]
Cenobamate	DM8KLU9	Complex partial seizure	8A68.0	Approved	[24]
Evenamide	DMWB94K	Schizophrenia	6A20	Phase 2	[25]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[26]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[28]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[29]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[30]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[31]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[32]
Metronidazole	DMTIVEN	Abscess		Approved	[33]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[34]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[2]
Voltage-gated sodium channel (Nav)	TTIG65Q	NOUNIPROTAC	Inhibitor	[3]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Inhibitor	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) Main DME	DEYGVN4	UD11_HUMAN	Substrate	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7350).
• [2] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [3] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [4] Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94.
• [5] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [6] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [7] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [8] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [9] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [10] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [13] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [14] WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
• [15] Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
• [16] The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
• [17] Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
• [18] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [19] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [20] Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
• [21] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [22] Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
• [23] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [24] Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182.
• [25] Clinical pipeline report, company report or official report of Newron Pharmaceuticals.
• [26] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [27] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [28] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [29] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [30] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [31] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [32] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [33] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [34] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [35] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.